Pharmaceutical administration systems containing a mixture of immunomodulators

Claim 2

A pharmaceutical administration system consisting of (a) a water soluble muramylpeptide, (b) gamma-interferon, (c) a phospholipid of the formula ##STR7## wherein n is one, two or three, R 1 and R 2 independently of each other represent alkyl, alkenyl or acyl each having 10-20 carbon atoms, and Y.sup.⊕ is the cation of a pharmaceutically acceptable base, (d) a phospholipid of the formula ##STR8## wherein n is two, three or four, R 1 and R 2 are defined as above and R 3 , R 4 and R 5 represent hydrogen or C 1 -C 4 -alkyl, and, optionally, a pharmaceutically acceptable carrier solution buffered to pH 7.0-7.8, and, optionally a pharmaceutically acceptable carrier in solid form.

Claim 3

A pharmaceutical administration system according to claim 1 consisting of (a) a muramylpeptide of the formula ##STR9## wherein X represents the groups --C(═O)-- or --C(═O)--O--; R 1 represents C 1 -C 4 -alkyl; R 2 , R 3 and R 4 indpendently of each other represent or C 1 -C 4 -alkyl; R 5 and R 6 independently of each other represent carbamoyl, carboxy or esterified carboxy; when R 3 is other than hydrogen, the configuration about the carbon atom designated (I*) is D; when R 4 is other than hydrogen the configuration about the carbon atom designated (2*) is L; and when R 5 is other than hydrogen the configuration about the carbon atom designated (3*) is D; or a pharmaceutically acceptable salt thereof, (b) purified, natural or recombinant human gamma interferon, (c) a phospholipid of the formula I wherein n, R 1 , R 2 and Y.sup.⊕ are defined as above, (d) a phospholipid of the formula II wherein n and R 1 to R 5 are defined as above, and, optionally, a pharmaceutically acceptable carrier solution buffered from pH 7.2 to 7.4.

Claim 4

A pharmaceutical administration system according to claim 1 consisting of (a) sodium-N-acetyl-D-muramyl-L-alanyl-D-isoglutamine or sodium-N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine, (b) purified, natural or recombinant human gamma interferon, (c) a phospholipid of the formula I wherein n is one, R 1 and R 2 are acyl each having 10 to 20 carbon atoms and Y.sup.⊕ is the sodium ion, (d) a phospholipid of the formula II wherein n is two, R 1 and R 2 are acyl each having 10 to 20 carbon atoms, and R 3 to R 5 represent hydrogen or methyl, and, optionally, a pharmaceutically acceptable carrier solution buffered from pH 7.2 to 7.4.

Claim 5

A pharmaceutical administration system according to claim 1 consisting of (a) sodium-N-acetyl-D-muramyl-L-alanyl-D-isoglutamine or sodium-N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine, (b) purified, natural or recombinant human gamma interferon, (c) a synthetic phospholipid of the formula I wherein n is one, R 1 and R 2 are identical C 10 -C 20 -alkenoyl groups and Y.sup.⊕ is the sodium ion, (d) a synthetic phospholipid of the formula II, wherein R 1 and R 2 are identical C 10 -C 20 -alkanoyl groups and R 3 to R 5 represent methyl, and optionally, a pharmaceutically acceptable carrioer solution buffered from pH 7.2 to 7.4.

Claim 6

A pharmaceutical administration system according to claim 1 consisting of (a) sodium-N-acetyl-D-muramyl-L-alanyl-D-isoglutamine or sodium-N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine, (b) purified, natural or recombinant, human gamma-interferon, (c) synthetic, essentially pure sodium-1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine (I), (d) synthetic, essentially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidylcholine (II), and, optionally, a pharmaceutically acceptable carrier solution.

Claim 7

A pharmaceutical administration system according to claim 1 consisting of (a) 50 to 200 microgramm of sodium-N-acetyl-D-muramyl-L-alanyl-D-isoglutamine or sodium-N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine, (b) about 1,000 to 100,000 units of recombinant gamma-interferon having the amino acid sequences: ##STR10## and approximately 200 mg to 1,000 mg of (c) synthetic, essentially pure sodium-1,2-di-(9-cis-octadecenoyl)-3-sn-phosphatidyl-(S)-serine(I) and (d) synthetic, essentially pure 1-n-hexadecanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidylcholine (II), wherein the molar ratio of the phospholipid component (c) to the phospholipid component (d) is about 30 to 70 mole percent, and, optionally, a pharmaceutically acceptable carrier solution.

Claim 8

A method of stimulating the immune system in humans or animals which comprises administering to a human or animal in need of such administration an effective amount of a pharmaceutical administration system as claimed in claim 1.

Claim 9

A method of activating macrophages or monocytes in humans which comprises administering to a human in need of such administration an effective amount of a pharmaceutical administration system as claimed in claim 1.